Therapeutic impact of 18F-FDG PET/CT for initial staging in patients with clinical stage I and IIA, HER2-positive, or triple-negative breast cancer
Breast Cancer Research and Treatment · 2024
DOI: 10.1007/s10549-024-07386-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Breast Cancer Research and Treatment, 2024. Verfasst von Chloé François und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Centre Oscar Lambret, 3 rue Combemale, 59020, Lille Cedex, France. chloe@francois.nom.fr. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Fluorodeoxyglucose F18, Neoplasm Staging, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: While 18F-FDG PET/CT (FDG-PET/CT) is consensual for clinical stage ≥ IIB breast cancers (BC), its benefit for stage I or IIA HER2+ or triple-negative breast cancer (TNBC) patients lacks sufficient evidence. We reported a single-institution, retrospective study evaluating FDG-PET/CT impact on patient management and staging for stage I or IIA HER2+ or Triple-Negative BC. METHODS: Patients who underwent FDG-PET/CT staging before any treatment between January 2015 and December 2020 at Oscar Lambret Center were included. EXCLUSIONS: patients with symptoms or conventional imaging suggestive of metastatic dissemination, or with prior malignancies. Initial stage was determined from mammography, breast ultrasound, breast MRI, and clinical examination. Staging and therapeutic impact based on FDG-PET/CT findings collected, including intra- (modification of dose/site/strategy in a type of management previously indicated) and inter-modality (modification of planned treatment strategy) changes. RESULTS: The cohort included 287 female patients with clinical stage I or IIA, HER2+ , or TNBC. Therapeutic impact observed for 18% of patients (n = 52), with 2% (n = 7) undergoing inter-modality change with omission of planned surgery. The impact on patient management was higher for stage IIA patients (20%, 47/237) than for stage I patients (10%, 5/50). Among stage IIA disease, changes in management were more important for T2N0 patients (22%, 44/205) than for T1N1 patients (9%, 3/32). While not statistically significant, trends suggest usefulness of FDG-PET/CT for T2N0 patients. CONCLUSION: Considering substantial therapeutic implications, our study suggests the usefulness of FDG-PET/CT for patients with stage IIA, HER2-positive, or Triple-Negative BC with tumor size > 2 cm (T2N0).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Centre Oscar Lambret, 3 rue Combemale, 59020, Lille Cedex, France. chloe@francois.nom.fr.
- Department of Medical Oncology, Centre Oscar Lambret, Lille, France.
- Methodology and Biostatistic Unit, Centre Oscar Lambret, Lille, France.
- Department of Nuclear Medicine, Centre Oscar Lambret, 3 rue Combemale, 59020, Lille Cedex, France.
- Department of Radiology, Centre Oscar Lambret, Lille, France.
- Department of Clinical Pharmacy, Centre Oscar Lambret, Lille, France.
Zitieren
APA
François, C., Mailliez, A., Chretien, S., Leguillette, C., Oudoux, A., Ceugnart, L., Barthoulot, M., Cougnenc, O., & Olivier, A. (2024). Therapeutic impact of 18F-FDG PET/CT for initial staging in patients with clinical stage I and IIA, HER2-positive, or triple-negative breast cancer. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-024-07386-8
Vancouver
François C, Mailliez A, Chretien S, Leguillette C, Oudoux A, Ceugnart L, et al. Therapeutic impact of 18F-FDG PET/CT for initial staging in patients with clinical stage I and IIA, HER2-positive, or triple-negative breast cancer. Breast Cancer Research and Treatment. 2024. doi:10.1007/s10549-024-07386-8
BibTeX
@article{Franois2024,
author = {François, Chloé and Mailliez, Audrey and Chretien, Sebastian and Leguillette, Clémence and Oudoux, Aurore and Ceugnart, Luc and Barthoulot, Maël and Cougnenc, Olivier and Olivier, Anaïs},
title = {Therapeutic impact of 18F-FDG PET/CT for initial staging in patients with clinical stage I and IIA, HER2-positive, or triple-negative breast cancer},
journal = {Breast Cancer Research and Treatment},
year = {2024},
doi = {10.1007/s10549-024-07386-8}
}
EUVIMED